These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration. Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925 [TBL] [Abstract][Full Text] [Related]
7. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092 [TBL] [Abstract][Full Text] [Related]
8. Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications. Liu J; Zhang X; Li G; Xu F; Li S; Teng L; Li Y; Sun F Int J Nanomedicine; 2019; 14():8819-8834. PubMed ID: 31819410 [TBL] [Abstract][Full Text] [Related]
9. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration. Park DH; Sun HJ; Lee SJ Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933 [TBL] [Abstract][Full Text] [Related]
11. Nanodelivery of doxorubicin for age-related macular degeneration. Kelly SJ; Halasz K; Smalling R; Sutariya V Drug Dev Ind Pharm; 2019 May; 45(5):715-723. PubMed ID: 30704311 [TBL] [Abstract][Full Text] [Related]
12. Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic Model. Hutton-Smith LA; Gaffney EA; Byrne HM; Caruso A; Maini PK; Mazer NA Mol Pharm; 2018 Jul; 15(7):2770-2784. PubMed ID: 29734810 [TBL] [Abstract][Full Text] [Related]
13. Individualizing the intravitreal anti-VEGF dosing regimen for long-term management of neovascular AMD. Freund KB; Engelbert M; Fine HF Ophthalmic Surg Lasers Imaging Retina; 2015 May; 46(5):508-12. PubMed ID: 26057753 [No Abstract] [Full Text] [Related]
14. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an update. Costagliola C; Morescalchi F; Duse S; Romano D; Mazza G; Parmeggiani F; Bartollino S; Semeraro F Expert Opin Drug Saf; 2019 Sep; 18(9):803-815. PubMed ID: 31309853 [No Abstract] [Full Text] [Related]
15. ANGIOPOIETIN-LIKE 4 CORRELATES WITH RESPONSE TO INTRAVITREAL RANIBIZUMAB INJECTIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Kim JH; Shin JP; Kim IT; Park DH Retina; 2018 Mar; 38(3):523-530. PubMed ID: 28151839 [TBL] [Abstract][Full Text] [Related]
16. [Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany]. Ziemssen F; Eter N; Fauser S; Bopp S; Radermacher M; Hasanbasic Z; Holz FG; Ophthalmologe; 2015 Mar; 112(3):246-54. PubMed ID: 25668709 [TBL] [Abstract][Full Text] [Related]
17. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration. Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246 [TBL] [Abstract][Full Text] [Related]